MIR379

Summary

MIR379 (microRNA 379, HGNC:31872) is a microRNA gene on chromosome 14q32.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 494328 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31872
Approved symbol	MIR379
Name	microRNA 379
Location	14q32.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-379
Ensembl gene	ENSG00000199088
Ensembl biotype	miRNA
OMIM	616358
Entrez	494328
RNAcentral	URS000075EEE5 — miRNA, 67 nt, 7 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362218

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362218 — 1 exons

Exon	Start	End
ENSE00001436981	101022066	101022132

Expression profiles

Bgee: expression breadth broad, 55 present calls, max score 92.12.

Top tissues by expression

55 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	92.12	gold quality
heart	UBERON:0000948	82.24	gold quality
kidney	UBERON:0002113	80.57	gold quality
gastrocnemius	UBERON:0001388	80.29	gold quality
stomach	UBERON:0000945	79.48	gold quality
blood	UBERON:0000178	78.92	gold quality
myometrium	UBERON:0001296	77.37	gold quality
left adrenal gland cortex	UBERON:0035825	76.53	gold quality
lung	UBERON:0002048	76.16	gold quality
placenta	UBERON:0001987	75.17	gold quality
intestine	UBERON:0000160	74.01	gold quality
islet of Langerhans	UBERON:0000006	72.69	gold quality
monocyte	CL:0000576	72.27	gold quality
colon	UBERON:0001155	72.04	gold quality
endometrium	UBERON:0001295	71.74	gold quality
lower esophagus muscularis layer	UBERON:0035833	71.36	gold quality
right adrenal gland cortex	UBERON:0035827	71.05	gold quality
muscle layer of sigmoid colon	UBERON:0035805	69.72	gold quality
left adrenal gland	UBERON:0001234	69.65	gold quality
body of stomach	UBERON:0001161	68.32	gold quality
left ovary	UBERON:0002119	68.32	gold quality
ascending aorta	UBERON:0001496	68.05	gold quality
transverse colon	UBERON:0001157	67.93	gold quality
omental fat pad	UBERON:0010414	67.92	gold quality
body of pancreas	UBERON:0001150	67.63	gold quality
esophagus mucosa	UBERON:0002469	67.33	gold quality
ovary	UBERON:0000992	67.22	gold quality
anterior cingulate cortex	UBERON:0009835	64.88	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	64.67	gold quality
minor salivary gland	UBERON:0001830	63.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 35)

• miR-379 is a novel regulator of Cyclin B1 expression, with significant loss of the miRNA observed in breast tumours. (PMID:23874748)
• This observation may suggest a differential suppression of ABCC2 by miR-379 caused by haplotype-dependent differences in mRNA secondary structures, resulting in changes in mRNA target accessibility or mRNA stability (PMID:24743544)
• miR-379 and miR-411 directly target the IL-18 gene and contribute to drug resistance in malignant pleural mesothelioma. (PMID:25231602)
• miR-154* and miR-379 play important roles in prostate cancer biology by facilitating tumor growth, EMT, and bone metastasis. (PMID:25324143)
• microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis. (PMID:25510864)
• In clinical samples of hepatocellular carcinom (HCC), miR-379-5p negatively correlated with FAK, which was up-regulated in HCC. (PMID:26944318)
• Data show that microRNA miR-379 potentiated lung cancer (LCa) chemosensitivity via modulation of cisplatin (CDDP)-induced apoptosis by directly targeting the eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) 3’ UTR. (PMID:28117895)
• These findings suggest that the miR-379-5p/MDM2 pathway plays an important role in bladder cancer and could serve as a potential candidate for bladder cancer therapeutics. (PMID:28498468)
• The ectopic overexpression of miR-379 inhibited cell migration, invasion and EMT progress, while downregulated miR-379 reversed the effect. In addition, miR-379 regulated the focal adhesion kinase (FAK) by directly binding to its 3’-UTR, resulting in suppression of AKT signaling. In clinical samples of gastric cancer (GC), miR-379 inversely correlated with FAK, which was upregulated in GC. (PMID:28713929)
• Up-regulation of miR-379 rescued the phenotype induced by overexpression of circHIPK3. (PMID:28738961)
• Low miR-379 expression is associated with Cervical Cancer. (PMID:29295725)
• These data first uncovered potentially pathogenic miR-379-5p and two novel targets PARP1 and XRCC6 in biochemical premature ovarian insufficiency. (PMID:29367615)
• miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of Mesenchymal stem cells while engineering the cells to secrete Extracellular vesicles enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer. (PMID:29367765)
• Mir379 underexpression is associated with glioblastoma. (PMID:29769662)
• Study performed the expression analysis of miR-379/miR-656 miRNA-cluster (C14MC) in oligodendrogliomas (ODGs) and also investigated the mechanism underlying modulation of this cluster; and found significant downregulation of majority of the miRNAs. Further data from The Cancer Genome Atlas (TCGA) also confirmed the global downregulation of C14MC. (PMID:29931616)
• miR379 inhibits cell proliferation and epithelialmesenchymal transition by targeting CHUK through the NFkappaB pathway in nonsmall cell lung cancer. (PMID:31173238)
• Study for the first time demonstrated that miR-379/TCF-4 (TCF7L2) might involve in the progression of laryngeal carcinoma, and miR-379 appears to serve as a novel tumor suppressor in laryngeal carcinoma. (PMID:31436384)
• circ-PITX1 exerted as a competing endogenous RNA (ceRNA) in glioblastoma by sponging miR-379-5p to elevate MAP3K2 expression (PMID:31493405)
• LINC00665 promotes breast cancer progression through regulation of the miR-379-5p/LIN28B axis. (PMID:31907362)
• MiR-30a and miR-379 modulate retinoic acid pathway by targeting DNA methyltransferase 3B in oral cancer. (PMID:32238162)
• miR3795p inhibits cell proliferation and promotes cell apoptosis in nonsmall cell lung cancer by targeting betaarrestin1. (PMID:33173959)
• AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p. (PMID:33984486)
• miR-379-5p inhibits proliferation and invasion of the endometrial cancer cells by inhibiting expression of ROR1. (PMID:34115460)
• MiR-379-5p targets microsomal glutathione transferase 1 (MGST1) to regulate human glioma in cell proliferation, migration and invasion and epithelial-mesenchymal transition (EMT). (PMID:34171541)
• Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery. (PMID:34433636)
• Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis. (PMID:34592879)
• MiR-379-5p inhibits the proliferation, migration, and invasion of breast cancer by targeting KIF4A. (PMID:35608059)
• Characterization of Adrenal miRNA-Based Dysregulations in Cushing’s Syndrome. (PMID:35887024)
• Hsa-miR-379 down-regulates Rac1/MLK3/JNK/AP-1/Collagen I cascade reaction by targeting connective tissue growth factor in human alveolar basal epithelial A549 cells. (PMID:37002970)
• Granulosa cell-derived miR-379-5p regulates macrophage polarization in polycystic ovarian syndrome. (PMID:37033997)
• Androgen-induced exosomal miR-379-5p release determines granulosa cell fate: cellular mechanism involved in polycystic ovaries. (PMID:37046285)
• GRB10 is a novel factor associated with gastric cancer proliferation and prognosis. (PMID:37179120)
• Circ_0010235 confers cisplatin resistance in lung cancer by upregulating E2F7 through absorbing miR-379-5p. (PMID:37277864)
• miR-379-5P INHIBITION ENHANCES INTESTINAL EPITHELIAL PROLIFERATION AND BARRIER FUNCTION RECOVERY AFTER ISCHEMIA/REPERFUSION BY TARGETING EIF4G2. (PMID:37646610)
• Regulation and tumor-suppressive function of the miR-379/miR-656 (C14MC) cluster in cervical cancer. (PMID:38400534)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.